Biomarkers of sarcopenia: an unmet need

IF 0.8 Q4 RHEUMATOLOGY
Mona El-Sebaie, Walaa Elwakil
{"title":"Biomarkers of sarcopenia: an unmet need","authors":"Mona El-Sebaie, Walaa Elwakil","doi":"10.1186/s43166-023-00213-w","DOIUrl":null,"url":null,"abstract":"Abstract Background Sarcopenia is a syndrome characterized by a progressive decline in muscle mass and strength, with subsequent deterioration of functional performance and increased morbidity and mortality. Its emergence may be associated with disorders that are not limited to the elderly. The multifactorial nature of sarcopenia is a major barrier to diagnosis. Several risk factors contribute to the development of sarcopenia, including age, gender, and amount of physical activity. Additionally, the pathophysiology of sarcopenia involves inflammatory conditions, endocrinal dysfunction, and metabolic alterations. Several studies have proposed numerous molecules that may be linked to the pathogenesis of sarcopenia and could be useful in the future; however, there is an unmet need to discover a sensitive, reliable, and cost-effective biomarker of muscle aging. Main text The objective of this research is to highlight different biomarkers of sarcopenia that reflect its multifactorial pathophysiology. A narrative review was carried out through a series of literature searches in the database MEDLINE/PubMed focusing on sarcopenia biomarkers. The following search terms were used: “sarcopenia,” “osteosarcopenia,” “muscle ageing,” “muscle failure,” “sarcopenic obesity,” “weakness,” “biomarkers,” “frailty,” “comorbidity,” “functional disability,” and “inflamm-aging.” The studies were observational and peer-reviewed. They were all carried out at a referral center, hospital, or in the community. The articles chosen all contained information about sarcopenia. Case reports and articles that did not assess people's muscle aging and sarcopenia were not considered. Conclusion Despite the availability of numerous functional, imaging, and biological sarcopenia markers, the inherent limitations of the assessment tools make it difficult to objectively measure the various sarcopenia domains. A valid and reliable biomarker of sarcopenia has yet to be identified. The identification of “gold standard” evaluation techniques that should be systematically used is also impacted by the variability of the populations to be assessed. In this context, the establishment of an international consensus adopting a multi-biomarker approach may be of utmost importance to tackle the different aspects of this multifactorial health-related problem.","PeriodicalId":31002,"journal":{"name":"Egyptian Rheumatology and Rehabilitation","volume":"1 1","pages":"0"},"PeriodicalIF":0.8000,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Rheumatology and Rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43166-023-00213-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Background Sarcopenia is a syndrome characterized by a progressive decline in muscle mass and strength, with subsequent deterioration of functional performance and increased morbidity and mortality. Its emergence may be associated with disorders that are not limited to the elderly. The multifactorial nature of sarcopenia is a major barrier to diagnosis. Several risk factors contribute to the development of sarcopenia, including age, gender, and amount of physical activity. Additionally, the pathophysiology of sarcopenia involves inflammatory conditions, endocrinal dysfunction, and metabolic alterations. Several studies have proposed numerous molecules that may be linked to the pathogenesis of sarcopenia and could be useful in the future; however, there is an unmet need to discover a sensitive, reliable, and cost-effective biomarker of muscle aging. Main text The objective of this research is to highlight different biomarkers of sarcopenia that reflect its multifactorial pathophysiology. A narrative review was carried out through a series of literature searches in the database MEDLINE/PubMed focusing on sarcopenia biomarkers. The following search terms were used: “sarcopenia,” “osteosarcopenia,” “muscle ageing,” “muscle failure,” “sarcopenic obesity,” “weakness,” “biomarkers,” “frailty,” “comorbidity,” “functional disability,” and “inflamm-aging.” The studies were observational and peer-reviewed. They were all carried out at a referral center, hospital, or in the community. The articles chosen all contained information about sarcopenia. Case reports and articles that did not assess people's muscle aging and sarcopenia were not considered. Conclusion Despite the availability of numerous functional, imaging, and biological sarcopenia markers, the inherent limitations of the assessment tools make it difficult to objectively measure the various sarcopenia domains. A valid and reliable biomarker of sarcopenia has yet to be identified. The identification of “gold standard” evaluation techniques that should be systematically used is also impacted by the variability of the populations to be assessed. In this context, the establishment of an international consensus adopting a multi-biomarker approach may be of utmost importance to tackle the different aspects of this multifactorial health-related problem.
肌肉减少症的生物标志物:一个未被满足的需求
背景肌肉减少症是一种以肌肉质量和力量进行性下降为特征的综合征,随之而来的是功能表现的恶化和发病率和死亡率的增加。它的出现可能与不限于老年人的疾病有关。肌少症的多因素性质是诊断的主要障碍。造成肌肉减少症的几个危险因素包括年龄、性别和运动量。此外,肌肉减少症的病理生理包括炎症、内分泌功能障碍和代谢改变。一些研究已经提出了许多可能与肌肉减少症发病机制有关的分子,这些分子在未来可能是有用的;然而,发现一种敏感、可靠、成本效益高的肌肉衰老生物标志物的需求尚未得到满足。本研究的目的是强调反映其多因素病理生理的肌肉减少症的不同生物标志物。通过在MEDLINE/PubMed数据库中检索一系列以肌肉减少症生物标志物为重点的文献进行叙述性回顾。使用了以下搜索词:“肌肉减少症”、“骨质减少症”、“肌肉老化”、“肌肉衰竭”、“肌肉减少性肥胖”、“虚弱”、“生物标志物”、“脆弱”、“共病”、“功能性残疾”和“炎症老化”。这些研究是观察性和同行评审的。他们都是在转诊中心、医院或社区进行的。所选的文章都包含有关肌肉减少症的信息。没有评估人们肌肉老化和肌肉减少症的病例报告和文章没有被考虑。尽管有许多功能性、影像学和生物学上的肌肉减少症标志物,但评估工具的固有局限性使得难以客观地测量各种肌肉减少症域。肌少症的有效和可靠的生物标志物尚未确定。确定应当系统使用的“金标准”评价技术也受到待评价人口的可变性的影响。在这种情况下,建立采用多种生物标志物方法的国际共识对于解决这一多因素健康相关问题的不同方面可能至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
25.00%
发文量
62
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信